Both heart failure and its treatment with diuretics or SGLT2 inhibitors increase fall risk in older adults. Therefore, decisions to continue or deprescribe diuretics or SGLT2 inhibitors in older heart failure patients who have fallen are generally highly complex and challenging for clinicians. However...
older adultsdrug safetySodium-glucose cotransporter 2 (SGLT2) inhibitors have been found to have many benefits for patients with type 2 diabetes. However, whether SGLT2 inhibitors increase the risk of acute kidney injury (AKI) remains unknown. We examined the association of AKI hospitalization with...
The sodium–glucose cotransporter 2 (SGLT2) inhibitors empagliflozin and dapagliflozin significantly reduce the risk of cardiovascular death or hospitalization for heart failure in patients with chronic heart failure with a reduced left ventricular ejection fraction (LVEF)9,10. Empagliflozin additionally sign...
1. Lin D S-H, et al. J Clin Endocrinol Metab. 2021; 106(7): 2133-2145. 2. Lunati ME, et al. Safety and efficacy of SGLT2-inhibitors in over 70 years old type 2 diabetic patients: 1 year of follow up. 2021EASD-OP 09-49....
However, as more CVOTs report results it is increasingly difficult and confusing for clinicians to choose between SGLT2 inhibitors for their patients. In this review, we compare SGLT2 inhibitors with completed CVOT results, illustrating similarities and differences in trial design, and key glycaemic,...
SGLT2 Inhibitors and Atherosclerosis: Potential Effect Modifiers SGLT2抑制剂与动脉粥样硬化:潜在效应调节因素 Various factors including sex, age, diabetes, glycemic control, ASCVD, and SGLT2-i compounds can modify the association ...
当前研究结果提示SGLT-2抑制剂是ATTR-CM有前景的治疗方案。 医脉通编译自:Frederick M Lang, Sergio Teruya, Ariel Weinsaft, et al. Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety. Eur J Heart Fail. 2024 Mar 15....
近日,一项美国研究显示,钠-葡萄糖共转运蛋白2抑制剂(SGLT-2i)或有助于改善转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)患者容量状况以及利尿剂抵抗。 研究显示,ATTR-CM患者中,与不用SGLT-2i相比,接受SGLT-2i治疗与随访期间体重、袢利尿剂剂量和尿酸均较治疗前显著降低。
例如,现有证据估计 SGLT2 抑制剂的血清尿酸降低幅度约为 1.8 mg/dl【Yokose C et al. Serum urate change among gout patients initiating sodium-glucose cotransporter type 2 inhibitors (SGLT2i) vs. sulfonylureas: a comparative effe...
30. Bapir R, Bhatti KH, Eliwa A, et al. Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis. Arch Ital Urol Androl. 2023;95:11509.